Viren Mehta, an industry analyst, argues that two recent shifts have conspired to put drugs bosses in a difficult position.
业内分析师Viren Mehta认为近来的两种转变综合起来,将制药公司老板置于艰难处境。
Generics firms will do better with biosimilars than they have with conventional generic drugs, insists Viren Mehta, an industry expert.
工业专家维伦梅塔表示,无专利保护制药公司制造生物仿制药品将会比制造传统的无专利保护药品更有优势。
应用推荐